<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study was designed to explore the mechanism of <z:chebi fb="0" ids="28775">hesperidin</z:chebi> action via the nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> pathway in the protection against ischemic reperfusion cerebral injury-induced <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory dysfunction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Male Wistar rats (200-220 g) were subjected to bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 30 min followed by 24 h reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="28775">Hesperidin</z:chebi> (50 and 100 mg/kg, po) pretreatment was given for 7 days before animals were subjected to cerebral I/R injury </plain></SENT>
<SENT sid="3" pm="."><plain>Various behavioral tests (rotarod performance and memory retention), biochemical parameters (<z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation, <z:chebi fb="95" ids="16301">nitrite</z:chebi> concentration, <z:chebi fb="0" ids="16856">glutathione</z:chebi> levels, <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase activity and catalase activity), <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex enzyme dysfunctions (complex I, II, III and IV) and histopathological alterations were subsequently assessed in hippocampus </plain></SENT>
<SENT sid="4" pm="."><plain>Seven days of <z:chebi fb="0" ids="28775">hesperidin</z:chebi> (50 and 100 mg/kg) treatment significantly improved neurobehavioral alterations (delayed fall off time and increased memory retention), oxidative defense and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> complex enzyme activities in hippocampus compared to control (I/R) animals </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="0" ids="28775">hesperidin</z:chebi> treatment significantly attenuated histopathological alterations compared to control (I/R) animals </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (100 mg/kg) pretreatment attenuated the protective effect of the lower dose of <z:chebi fb="0" ids="28775">hesperidin</z:chebi> on memory behavior, biochemical and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction compared with <z:chebi fb="0" ids="28775">hesperidin</z:chebi> alone </plain></SENT>
<SENT sid="7" pm="."><plain>However, L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> pretreatment significantly potentiated the protective effect of <z:chebi fb="0" ids="28775">hesperidin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The present study suggests that the <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi>-NO signaling pathway is involved in the protective effect of <z:chebi fb="0" ids="28775">hesperidin</z:chebi> against cerebral I/R-induced <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory dysfunction</z:e> and biochemical alterations in rats </plain></SENT>
</text></document>